GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Isleworth Healthcare Acquisition Corp (NAS:ISLE) » Definitions » Deferred Tax

Isleworth Healthcare Acquisition (Isleworth Healthcare Acquisition) Deferred Tax

: $0.00 Mil (TTM As of Jun. 2022)
View and export this data going back to 2021. Start your Free Trial

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Isleworth Healthcare Acquisition's change in deferred tax for the three months ended in Jun. 2022 was $0.00 Mil. Its change in deferred tax for the trailing twelve months (TTM) ended in Jun. 2022 was $0.00 Mil.

Isleworth Healthcare Acquisition Deferred Tax Historical Data

The historical data trend for Isleworth Healthcare Acquisition's Deferred Tax can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Isleworth Healthcare Acquisition Annual Data
Trend Dec20 Dec21
Deferred Tax
- -

Isleworth Healthcare Acquisition Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Deferred Tax Premium Member Only - - - - -

Isleworth Healthcare Acquisition Deferred Tax Calculation

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Deferred Tax for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Isleworth Healthcare Acquisition Deferred Tax Related Terms

Thank you for viewing the detailed overview of Isleworth Healthcare Acquisition's Deferred Tax provided by GuruFocus.com. Please click on the following links to see related term pages.

Isleworth Healthcare Acquisition (Isleworth Healthcare Acquisition) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Isleworth Healthcare Acquisition Corp (NAS:ISLE) » Definitions » Deferred Tax
Comparable Companies
AVAC TRCA IFIN WAVC IQMD FRW SHCA OCA BIOT DWIN GSHN PSTH XAMS:EPIC ASZ CCYC CVII KAHC DWAC IPOF PBAJ
Traded in Other Exchanges
N/A
Address
360 Central Avenue, First Central Tower, Suite No. 800, Saint Petersburg, FL, USA, 33701
Website
https://www.isleworthhealthcare.com
Isleworth Healthcare Acquisition Corp is a blank check company.

Isleworth Healthcare Acquisition (Isleworth Healthcare Acquisition) Headlines

From GuruFocus

Cytovia Therapeutics to Present In Vivo Multiple Myeloma Data of its CD38-Targeting Flex-NK� Cell Engager at EHA 2022 Congress

By PRNewswire PRNewswire • 07-07-2022

Cytovia Therapeutics to Present at AACR Special Conference on Advances in the Pathogenesis and Molecular Therapies of Liver Cancer

By PRNewswire PRNewswire • 07-05-2022

Cytovia Therapeutics to Present at AACR Special Conference on Advances in the Pathogenesis and Molecular Therapies of Liver Cancer

By PRNewswire PRNewswire • 05-06-2022

Isleworth Healthcare Acquisition Corp. Announces Closing of $207,000,000 Initial Public Offering, Including Full Exercise of Underwriter Over-Allotment Option

By PRNewswire PRNewswire • 03-03-2021

Cytovia Therapeutics presents antitumor activity of its CD38-Targeting Flex-NK� Cell Engager antibody at EHA 2022 Congress

By PRNewswire PRNewswire • 06-30-2022

ISLEWORTH AND CYTOVIA TERMINATE MERGER AGREEMENT

By PRNewswire PRNewswire • 06-30-2022

Cytovia Therapeutics to Present at AACR Special Conference on Advances in the Pathogenesis and Molecular Therapies of Liver Cancer

By PRNewswire PRNewswire • 06-25-2022

Isleworth Healthcare Acquisition Corp. Announces Cancellation of Special Meeting of Shareholders, Redemption of Public Shares and Subsequent Dissolution

By PRNewswire PRNewswire • 08-25-2022

Cytovia Therapeutics to Present at AACR Special Conference on Advances in the Pathogenesis and Molecular Therapies of Liver Cancer

By PRNewswire PRNewswire • 05-26-2022

Cytovia Therapeutics presents antitumor activity of its CD38-Targeting Flex-NK� Cell Engager antibody at EHA 2022 Congress

By PRNewswire PRNewswire • 07-10-2022